What's Happening?
Inhibrx Biosciences has announced that the U.S. FDA has accepted its Biologics License Application (BLA) for ozekibart, a treatment for unresectable or metastatic conventional chondrosarcoma. This acceptance marks a significant milestone as ozekibart could
become the first FDA-approved treatment for this aggressive bone cancer. The BLA is supported by positive results from the ChonDRAgon study, which demonstrated a statistically significant improvement in progression-free survival for patients treated with ozekibart compared to placebo. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027, for its decision.
Why It's Important?
The acceptance of the BLA for ozekibart is a critical development for patients with chondrosarcoma, a rare and aggressive cancer with limited treatment options. If approved, ozekibart would provide a new therapeutic option for patients who currently rely on surgical resection as the primary treatment. This could significantly improve patient outcomes and quality of life. For Inhibrx, this represents a potential breakthrough in their clinical pipeline, positioning them as a leader in developing novel treatments for rare cancers.
What's Next?
The FDA's review process will continue until the PDUFA date in April 2027. During this time, Inhibrx will work closely with the FDA to address any questions or concerns that arise. If approved, ozekibart will be the first commercial product for Inhibrx, potentially opening new avenues for further research and development in oncology. The company is also exploring the use of ozekibart in other cancer types, which could expand its therapeutic applications.
